Pre-Treatment Positron Emission Topography Scanning for Increasing Success in Antidepressant Treatment

• Status: Completed
• Trial end date: 2012-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will use pre-treatment positron emission topography and functional magnetic resonance imaging scans of the brain to predict the most effective antidepressant treatment for people with major depressive disorder.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: New York State Psychiatric Institute
• Collaborator: National Institute of Mental Health (NIMH)
• Treatments: Antidepressive Agents; Citalopram; Desipramine; Dexetimide

Criteria

Inclusion Criteria:

• Diagnosis of current major depressive disorder

• Currently depressed

• Subjects must be generally healthy with no significant medical problems, anemia/blood loss, or cardiac abnormalities

• Likely to tolerate medication washout

• Capacity to provide informed consent

• Off of anti-coagulant/anti-platelet treatment for 10 days

• Willing to travel to Brookhaven for PET scanning

Exclusion Criteria:

• Current abuse of or dependence on alcohol or another substance (>6 months remission okay)

• History of other major psychiatric disorders such as bipolar, schizophrenia, schizoaffective; anorexia or bulimia in past year

• First degree family history of schizophrenia if subject is under 33

• Unable/unwilling to discontinue all psychotropic medication that affects the serotonin system

• Pregnant, breastfeeding, or planning to become pregnant during the study

• A medical contraindication to antidepressants

• Dementia

• Prior head trauma with evidence of cognitive impairment

• Well-documented failure of two or more SSRI AND tricyclic antidepressant (TCA) trials of adequate dose and duration

• Metal implants, pacemaker, metal protheses or orthodontic appliance, the presence of shrapnel

• Current past, present, or anticipated exposure to radiation

• Actively suicidal

• Lifetime history of glaucoma

• Lack of response to >2 trials of antidepressant monotherapy of adequate dose and duration

• Claustrophobia